APA (7th ed.) Citation

Dluzynski, D., Ssentongo, P., Hale, C. M., Shaheen, S. K., Maglakelidze, N., Sivik, J. M., . . . Paules, C. I. Dose-dependent impact of tixagevimab–cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals. Nature Portfolio.

Chicago Style (17th ed.) Citation

Dluzynski, Daniela, Paddy Ssentongo, Cory M. Hale, Shareef K. Shaheen, Natella Maglakelidze, Jeffrey M. Sivik, Maria Paula Henao, Vernon M. Chinchilli, and Catharine I. Paules. Dose-dependent Impact of Tixagevimab–cilgavimab as Primary Prevention Against SARS-CoV-2 in Immunocompromised Individuals. Nature Portfolio.

MLA (9th ed.) Citation

Dluzynski, Daniela, et al. Dose-dependent Impact of Tixagevimab–cilgavimab as Primary Prevention Against SARS-CoV-2 in Immunocompromised Individuals. Nature Portfolio.